Ernest Arenas


Affiliation: Karolinska Institutet
Country: Sweden


  1. Theofilopoulos S, Abreu de Oliveira W, Yang S, Yutuc E, Saeed A, Abdel Khalik J, et al. 24(S),25-Epoxycholesterol and cholesterol 24S-hydroxylase (CYP46A1) overexpression promote midbrain dopaminergic neurogenesis in vivo. J Biol Chem. 2019;294:4169-4176 pubmed publisher
    ..We propose that increasing the levels of 24,25-EC in vivo may be a useful strategy to combat the loss of mDA neurons in Parkinson's disease. ..
  2. Kaiser K, Gyllborg D, Prochazka J, Salasova A, Kompaníková P, Molina F, et al. WNT5A is transported via lipoprotein particles in the cerebrospinal fluid to regulate hindbrain morphogenesis. Nat Commun. 2019;10:1498 pubmed publisher
    ..Our study thus identifies the CSF as a route and lipoprotein particles as a vehicle for long-range transport of biologically active WNT in the central nervous system. ..
  3. Gyllborg D, Ahmed M, Toledo E, Theofilopoulos S, Yang S, Ffrench Constant C, et al. The Matricellular Protein R-Spondin 2 Promotes Midbrain Dopaminergic Neurogenesis and Differentiation. Stem Cell Reports. 2018;11:651-664 pubmed publisher
  4. Ribeiro D, Laguna Goya R, Ravindran G, Vuono R, Parish C, Foldi C, et al. Efficient expansion and dopaminergic differentiation of human fetal ventral midbrain neural stem cells by midbrain morphogens. Neurobiol Dis. 2013;49:118-27 pubmed publisher
    ..This method could substantially reduce the amount of human fetal midbrain tissue necessary for CRT in patients with PD, which could have major implications for the widespread adoption of this approach. ..
  5. Arenas E, Denham M, Villaescusa J. How to make a midbrain dopaminergic neuron. Development. 2015;142:1918-36 pubmed publisher
    ..Current challenges and future avenues in the development of a regenerative medicine for PD will be identified and discussed. ..
  6. La Manno G, Gyllborg D, Codeluppi S, Nishimura K, Salto C, Zeisel A, et al. Molecular Diversity of Midbrain Development in Mouse, Human, and Stem Cells. Cell. 2016;167:566-580.e19 pubmed publisher
    ..Thus, our study provides insight into the molecular programs controlling human midbrain development and provides a foundation for the development of cell replacement therapies. ..
  7. Villaescusa J, Li B, Toledo E, Rivetti di Val Cervo P, Yang S, Stott S, et al. A PBX1 transcriptional network controls dopaminergic neuron development and is impaired in Parkinson's disease. EMBO J. 2016;35:1963-78 pubmed publisher
    ..Thus, our results reveal novel roles for PBX1 and its transcriptional network in mDAn development and PD, opening the door for new therapeutic interventions. ..
  8. Salasova A, Yokota C, Potesil D, Zdrahal Z, Bryja V, Arenas E. A proteomic analysis of LRRK2 binding partners reveals interactions with multiple signaling components of the WNT/PCP pathway. Mol Neurodegener. 2017;12:54 pubmed publisher
    ..Since this balance is crucial for homeostasis of midbrain dopaminergic neurons, we hypothesize that its alteration may contribute to the pathophysiology of Parkinson's disease. ..
  9. Zhang D, Yang S, Toledo E, Gyllborg D, Salto C, Carlos Villaescusa J, et al. Niche-derived laminin-511 promotes midbrain dopaminergic neuron survival and differentiation through YAP. Sci Signal. 2017;10: pubmed publisher
    ..We propose that by enhancing LM511-YAP signaling, it may be possible to prevent mDA neuron degeneration in PD or enhance the survival of mDA neurons in cell replacement therapies. ..